Business Description

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. Monopar currently has three compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis (SOM) in patients undergoing radiotherapy for oropharyngeal cancer (OPC); Camsirubicin (MNPR-201 formerly GPX-150), a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs; and MNPR-101 (formerly huATN-658), a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers.

Company Info

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

(847) 388-0349